Takeda Pharmaceutical (TAK) Projected to Post Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) will likely be posting its Q3 2026 results before the market opens on Thursday, January 29th. Analysts expect the company to announce earnings of $0.55 per share and revenue of $7.8144 billion for the quarter. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, January 29, 2026 at 5:30 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.44 EPS for the quarter, hitting the consensus estimate of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The business had revenue of $7.30 billion during the quarter, compared to analyst estimates of $8.01 billion. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Down 0.3%

TAK stock opened at $16.11 on Thursday. Takeda Pharmaceutical has a fifty-two week low of $12.80 and a fifty-two week high of $16.48. The business’s 50 day moving average price is $15.06 and its two-hundred day moving average price is $14.72. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37. The company has a market capitalization of $51.25 billion, a price-to-earnings ratio of 201.31 and a beta of 0.03.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. UBS Group AG boosted its holdings in Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Takeda Pharmaceutical by 132.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after acquiring an additional 1,610,088 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after purchasing an additional 1,426,184 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Takeda Pharmaceutical by 225.8% during the second quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock valued at $16,035,000 after purchasing an additional 718,805 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Morgan Stanley assumed coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.